نتائج البحث

Futibatinib.

Subjects: Pyrazoles* ; Pyrimidines*; Humans

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2023 Apr 08; Vol. 80 (8), pp. 470-472.Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium:

تفاصيل العنوان

Stability-Indicating RP-HPLC Method Development and Validation for Eltrombopag Olamine in the Presence of Impurities and Degradation Products. Robustness by Design of Expert Software.

• Authors : Dandabattina R; Department of Chemistry, Bhavans Vivekananda College of Science, Sainikpuri, Secunderabad, Telangana 500094, India.; Department of Chemistry, GITAM School of Science, GITAM deemed to be University, Bengaluru, Karnataka 562163, India.

Subjects: Pyrazoles*; Drug Stability ; Chromatography, High Pressure Liquid/Chromatography, High Pressure Liquid/Chromatography, High Pressure Liquid/methods

• Source: Journal of AOAC International [J AOAC Int] 2023 Mar 01; Vol. 106 (2), pp. 267-275.Publisher: Oxford University Press Country of Publication: England NLM ID: 9215446 Publication Model: Print Cited Medium:

تفاصيل العنوان

Omidenepag Isopropyl.

Subjects: Pyridines* ; Pyrazoles*; Humans

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2023 Jan 24; Vol. 80 (3), pp. 93-95.Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium:

تفاصيل العنوان

Asciminib Hydrochloride.

Subjects: Niacinamide*/Niacinamide*/Niacinamide*/analogs & derivatives ; Pyrazoles*; Humans

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2022 Feb 08; Vol. 79 (4), pp. 207-210.Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium:

تفاصيل العنوان

Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.

• Authors : Roubal K; School of Pharmacy, University of Wisconsin, Madison, WI.; Myint ZW

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*administration & dosage ; Pyrazoles/Pyrazoles/Pyrazoles/*administration & dosage ; Quinoxalines/Quinoxalines/Quinoxalines/*administration & dosage

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2020 Feb 19; Vol. 77 (5), pp. 346-351.Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium:

تفاصيل العنوان

Pralsetinib.

Subjects: Pyrazoles* ; Pyrimidines*; Humans

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2021 Jan 01; Vol. 78 (1), pp. 1-3.Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium:

تفاصيل العنوان

Selpercatinib.

Subjects: Drug Labeling*; Carcinoma, Neuroendocrine/Carcinoma, Neuroendocrine/Carcinoma, Neuroendocrine/*drug therapy ; Oncogene Proteins, Fusion/Oncogene Proteins, Fusion/Oncogene Proteins, Fusion/*antagonists & inhibitors Thyroid cancer, medullary

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2020 Oct 30; Vol. 77 (22), pp. Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium:

تفاصيل العنوان

Possible apixaban-induced leukocytoclastic vasculitis.

• Authors : Daul B; Drake University College of Pharmacy and Health Sciences, Des Moines, IA.; Petersen G

Subjects: Factor Xa Inhibitors/Factor Xa Inhibitors/Factor Xa Inhibitors/*adverse effects ; Pyrazoles/Pyrazoles/Pyrazoles/*adverse effects ; Pyridones/Pyridones/Pyridones/*adverse effects Erythema elevatum diutinum

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2020 Aug 20; Vol. 77 (17), pp. Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium:

تفاصيل العنوان

Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review.

• Authors : Smith AR; Department of Pharmaceutical Services, Sanford USD Medical Center, Sioux Falls, SD.; Dager WE

Subjects: Anticoagulants/Anticoagulants/Anticoagulants/*administration & dosage ; Heparin/Heparin/Heparin/*administration & dosage ; Pyrazoles/Pyrazoles/Pyrazoles/*administration & dosage

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2020 Aug 20; Vol. 77 (Suppl 3), pp. Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium:

تفاصيل العنوان

Compliance with the riociguat risk evaluation and mitigation strategies program at an academic medical center.

• Authors : Riester MR; Department of Pharmacy, Lifespan Health System-Rhode Island Hospital Providence, RI.; Greene RA

Subjects: Enzyme Activators/Enzyme Activators/Enzyme Activators/*administration & dosage ; Pyrazoles/Pyrazoles/Pyrazoles/*administration & dosage ; Pyrimidines/Pyrimidines/Pyrimidines/*administration & dosage

• Source: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2020 Feb 19; Vol. 77 (5), pp. 328-330.Publisher: Oxford University Press Country of Publication: England NLM ID: 9503023 Publication Model: Print Cited Medium:

تفاصيل العنوان